Biomea Fusion

Edit info

Founded: 2017

Location: Redwood City, CA

Employee range: 50 - 200

Clinical stage: Clin1/Clin2

Therapy area: Diabetes (2)

Drug types: ONC, END

Lead product: BMF-219

Funding: $172.5M stock Mar 2023; $153M IPO Apr 2021; $56M A Jan 2021

biomeafusion.com

linkedin.com

job board

Drug notes:

Also 7 trials Clin1 multiple cancers; BMF-500 Clin0 AML, CLL; undisclosed RD oncology

About:

Biomea Fusion is developing novel small molecules to treat genetically defined diseases with high unmet need. Genetically defined diseases have biomarker-identifiable patient populations that Biomea can target with in silico designed small molecules with new mechanisms of action. This approach employs Biomea’s FUSIONTM System discovery platform that uses novel chemical scaffolds and a computational platform to produce optimized product profiles with high potency and safety. Biomea’s research and development has so far produced three novel, covalent inhibitor programs. Biomea recently received FDA clearance for IND application for their oral menin inhibitor, BMF-219, in type 2 diabetes. BMF-219 is also being developed as a cancer therapy.